Immune Biomarker Analysis in Patients with Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin and Treated with Chemoradiotherapy Using Docetaxel

What this Trial Is About

Researchers are studying patients with squamous cell carcinoma of the head and neck who cannot receive cisplatin and are treated with chemoradiotherapy using docetaxel. The study aims to identify immune biomarkers from tumor tissue, saliva, stool, and blood samples collected during routine care. These biomarkers will be analyzed alongside clinical data to find possible predictors of treatment feasibility, survival, tumor control, and increased tumor immunogenicity. Participants will undergo analysis of already available tumor tissue from pathology and provide saliva, stool, and blood samples as part of routine collection. The study focuses on patients who are unfit for cisplatin chemotherapy and receive chemoradiation with docetaxel. No investigational drugs are administered as part of the study samples and clinical data are collected and evaluated over the course of the trial. Participants involvement includes allowing the use of their existing tumor tissue and providing additional biological samples during routine care. Researchers will assess these samples and clinical information to measure feasibility of chemoradiotherapy with docetaxel and correlate immune profiles with overall survival, local tumor control, side effects, and treatment complications. The study duration is approximately 61 months, during which participants are monitored through clinical data and sample analysis.

Immune Biomarker Study for Cisplatin-ineligible Patients Receiving Chemoradiotherapy With Docetaxel